Research Advance of the Mechanisms, Clinical Characteristics and Treatment Strategy of Coagulation Dysfunction in Hemophagocytic Lymphohistiocytosis --Review.
10.19746/j.cnki.issn.1009-2137.2022.03.048
- Author:
Jing KANG
1
;
Shi-Xuan WANG
1
;
Fei LI
2
Author Information
1. Center of Hematology, The First Affiliated Hospital of Nanchang University, Institute of Hematology, Academy of Clinical Medicine of Jiangxi Province, Institute of Lymphoma and Myeloma in Nanchang University, Nanchang 330006, Jiangxi Province, China.
2. Center of Hematology, The First Affiliated Hospital of Nanchang University, Institute of Hematology, Academy of Clinical Medicine of Jiangxi Province, Institute of Lymphoma and Myeloma in Nanchang University, Nanchang 330006, Jiangxi Province, China,E-mail:yx021021@sina.com.
- Publication Type:Review
- Keywords:
coagulation dysfuction;
hemophagocytic lymphohistiocytosis;
mechanism;
prognosis
- MeSH:
Afibrinogenemia;
Blood Coagulation Disorders/therapy*;
Humans;
Lymphohistiocytosis, Hemophagocytic/therapy*;
Prognosis;
Thrombocytopenia
- From:
Journal of Experimental Hematology
2022;30(3):959-964
- CountryChina
- Language:Chinese
-
Abstract:
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disease caused by uncontrolled proliferation of activated macrophage, and secreting high amounts of inflammatory cytokines which lead to multi-organ dysfunction syndrome. HLH patients often show different clinical characteristics during the disease was progressed, in which coagulopathy were the most common, including thrombocytopenia and hypofibrinogenemia, those are the major cause of death in patients, and the clinicians should increase awareness of the mechanisms, clinical characteristics, prognosis and treatment. In this review, the above problems are briefly summarized, to deepen understanding of the HLH related coagulation dysfunctions, and early identification and treatment to reduce mortality, so as to provide more opportunities for HLH patients to recieve subsequent treatment.
